Whittier Trust Co. Sells 5,331 Shares of Elevance Health, Inc. $ELV

Whittier Trust Co. trimmed its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 27.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,922 shares of the company’s stock after selling 5,331 shares during the quarter. Whittier Trust Co.’s holdings in Elevance Health were worth $4,213,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Murphy Middleton Hinkle & Parker Inc. bought a new position in Elevance Health in the fourth quarter worth about $5,941,000. Bright Rock Capital Management LLC bought a new stake in shares of Elevance Health in the 4th quarter valued at about $7,362,000. Prana Capital Management LP boosted its holdings in shares of Elevance Health by 798.9% in the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock valued at $16,684,000 after buying an additional 45,889 shares in the last quarter. CIBC Bancorp USA Inc. purchased a new position in shares of Elevance Health in the 3rd quarter worth approximately $10,047,000. Finally, Loews Corp raised its stake in shares of Elevance Health by 107.5% during the 3rd quarter. Loews Corp now owns 110,000 shares of the company’s stock worth $35,543,000 after acquiring an additional 57,000 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Performance

Elevance Health stock traded up $8.86 during mid-day trading on Tuesday, reaching $417.03. 205,181 shares of the company traded hands, compared to its average volume of 1,815,026. The firm’s fifty day moving average is $391.29 and its two-hundred day moving average is $351.07. The company has a market capitalization of $90.56 billion, a price-to-earnings ratio of 17.76, a price-to-earnings-growth ratio of 2.37 and a beta of 0.67. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $427.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping the consensus estimate of $10.74 by $1.84. The business had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, equities research analysts expect that Elevance Health, Inc. will post 26.86 earnings per share for the current fiscal year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th were given a dividend of $1.72 per share. The ex-dividend date of this dividend was Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health’s payout ratio is currently 29.26%.

Insider Buying and Selling

In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares in the company, valued at approximately $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Mizuho increased their target price on shares of Elevance Health from $435.00 to $465.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. Deutsche Bank Aktiengesellschaft upgraded Elevance Health from a “hold” rating to a “buy” rating and increased their price objective for the company from $363.00 to $498.00 in a report on Wednesday, May 20th. Bank of America boosted their target price on Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research note on Thursday, June 4th. Raymond James Financial set a $450.00 target price on Elevance Health in a research report on Tuesday. Finally, Barclays increased their price target on Elevance Health from $408.00 to $480.00 and gave the company an “overweight” rating in a research note on Tuesday, May 26th. Fifteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $422.10.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.